CS
DNLI icon

Candriam SCA’s Denali Therapeutics DNLI Stock Holding History

Candriam SCA’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6M Buy
1,189,886
+90,041
+8% +$1.85M 0.14% 151
2026
Q1 		$21.1M Sell
1,099,845
-66,534
-6% -$1.32M 0.11% 186
2025
Q4 		$19.3M Buy
1,166,379
+332,797
+40% +$5.62M 0.1% 192
2025
Q3 		$12.1M Sell
833,582
-10,667
-1% -$153K 0.06% 249
2025
Q2 		$11.8M Sell
844,249
-13,913
-2% -$196K 0.07% 224
2025
Q1 		$11.7M Buy
858,162
+25,185
+3% +$483K 0.07% 223
2024
Q4 		$17M Sell
832,977
-109,181
-12% -$2.8M 0.1% 190
2024
Q3 		$27.4M Buy
942,158
+215,659
+30% +$5.35M 0.16% 137
2024
Q2 		$16.9M Buy
726,499
+278,621
+62% +$5.35M 0.1% 197
2024
Q1 		$9.19M Buy
447,878
+90,000
+25% +$1.69M 0.06% 265
2023
Q4 		$7.68M Hold
357,878
– – 0.05% 290
2023
Q3 		$7.38M Hold
357,878
– – 0.05% 263
2023
Q2 		$10.6M Hold
357,878
– – 0.08% 240
2023
Q1 		$7.59M Hold
357,878
– – 0.05% 298
2022
Q4 		$9.95M Hold
357,878
– – 0.07% 279
2022
Q3 		$11M Buy
357,878
+34,996
+11% +$1.14M 0.08% 246
2022
Q2 		$9.5M Buy
322,882
+181,375
+128% +$4.75M 0.08% 231
2022
Q1 		$4.55M Hold
141,507
– – 0.03% 367
2021
Q4 		$6.31M Buy
141,507
+77,726
+122% +$3.68M 0.04% 315
2021
Q3 		$3.22M Hold
63,781
– – 0.02% 482
2021
Q2 		$5M Buy
+63,781
New +$3.95M 0.03% 405

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's DNLI Position: Q2 2026 in Review

Candriam SCA increased its Denali Therapeutics (DNLI) stake by 8.2% in Q2 2026, buying an estimated $1.85M and bringing the position to 1,189,886 shares worth $30.6M. The position accounts for 0.14% of the portfolio, ranked #151.

Candriam SCA first reported a position in DNLI in Q2 2021 and has held it in 21 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Candriam SCA held 1,189,886 shares of Denali Therapeutics worth $30.6M as of Q2 2026.
  • Candriam SCA bought 90,041 Denali Therapeutics shares in Q2 2026, an estimated $1.85M.
  • Denali Therapeutics made up 0.14% of Candriam SCA's portfolio in Q2 2026, its #151 holding.
  • Candriam SCA first reported a position in Denali Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.